Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Context Therapeutics Inc. (CNTX)

Context Therapeutics receives Nasdaq notice over $1.00 minimum bid price

Negative Impact 3 of 5 legal/regulatory Written later

Context Therapeutics received a Nasdaq notice on July 29, 2026 stating its common stock failed to maintain a $1.00 minimum closing bid price for 30 consecutive business days. The company has until January 25, 2027 to regain compliance, and the notice has no immediate effect on its listing or trading, but failure to regain compliance could lead to delisting proceedings.

Key points

  • Nasdaq notice dated July 29, 2026 cites Listing Rule 5550(a)(2), the minimum bid price rule
  • Compliance deadline is January 25, 2027, after a 180 calendar day initial period
  • Company may be eligible for an additional 180-day Second Compliance Period if it meets listing requirements and notifies Nasdaq of its intent to cure
  • The notice has no immediate effect on the company's listing or trading

The filing

CompanyContext Therapeutics Inc. (CNTX)
Form8-K, current report
Filed with the SECJul 31, 2026, 4:08 PM ET
Accession number0001628280-26-051399

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.